PMID 3169264
2024;10:e8da1557
Hiramatsu M, Edamatsu R, Fujikawa N, Shirasu A, Yamamoto M, Suzuki S, Mori A: Measurement during convulsions of guanidino compound levels in cerebrospinal fluid collected with a catheter inserted into the cisterna magna of rabbits
5,12,13 These efforts have yielded six GLP-1 RAsstarting with the development of exendin-4 (Figure 1B)-based exenatide (Figure 1C), followed by liraglutide (Figure 1D), albiglutide, dulaglutide (Figure 1E), lixisenatide, and semaglutide (Figure 1F)that have been approved by the United States Food and Drug Administration (US FDA) to treat type 2 diabetes
The compound has attracted significant scientific interest because of its defined molecular structure, receptor affinity profile and suitability for controlled laboratory studies
As coverage policies evolve and formulations change, staying informed will help you make the most cost-effective decision for your care